Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a randomized ,opened, prospective controlled trial of clinical effectiveness for Icotinib as the adjunctive treatment after surgery in stage I-IIIB lung adenocarcinoma patients with epidermal growth factor receptor gene mutation
Epistemonikos ID: 4873e99f6d5d36eda33a2f7bfb91ac275aad058b
First added on: May 12, 2024